Real-world data reinforce SGLT2 inhibitors as first-line therapy for frail, older adults with heart failure with preserved ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...

In a study from Korea, adults with type 2 diabetes had a lower risk for autoimmune rheumatic diseases after starting an SGLT2 ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 inhibitor (SGLT2-i) slows nodule growth and reduces the need for surgical ...

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on ...

SGLT2 inhibitors show significant benefits in older adults with cardiovascular disease, with consistent benefits across subgroups based on diabetes status or age, a meta-analysis shows.

Fibrosis occurs when inflammation activates immune cells and fibroblasts to release collagen and cytokines that remodel and ...

The diabetes drug empagliflozin (Jardiance) and an insulin nasal spray both showed promising effects on memory, brain health ...

Ozempic, a GLP-1 receptor drug originally for diabetes, has become a major player in the weight loss industry—raising ...

Orforglipron, a novel oral GLP-1, was superior to dapagliflozin for reducing HbA1c in adults with type 2 diabetes ...

The scenario of chronic kidney disease (CKD) management has been transformed by the advent of sodium glucose co-transporter-2 (SGLT2) inhibitors, a class of drugs with benefits extending well beyond ...

Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in ...